UBS analyst Kevin Caliendo initiated coverage of Solventum (SOLV) with a Neutral rating and $77 price target The firm sees the company’s growth moderating in the near term due to industry SKU rationalization and tougher compares. It views the shares as appropriately valued given Solventum’s current portfolio setup.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SOLV:
- Solventum Corporation: Hold Rating Amid Balanced Valuation and Growth Challenges
- Strategic Business Sale and Optimistic Financial Targets Justify Buy Rating for Solventum Corporation
- Solventum price target raised to $82 from $79 at Wells Fargo
- Hold Rating on Solventum Corporation: Steady Growth and Valuation Challenges Post-Spin-Off
- Solventum initiated with a Hold at Jefferies